Viemed Healthcare (VMD) AI Stock Analysis

• Market Cap: $264.13M
• Dividend Yield: N/A
• Average Volume (3M): 317.53K
• Price to Earnings (P/E): 20.1
• Beta (1Y): 1.12
• Revenue Growth: 17.11%
• EPS Growth: 45.34%
• Country: US
• Employees: 1,222
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Devices
• EPS (TTM): 0.08
• Shares Outstanding: 38,785,760
• 10 Day Avg. Volume: 240,113
• 30 Day Avg. Volume: 317,531
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 1.13
• Enterprise Value/Gross Profit: 1.95
• Enterprise Value/Ebitda: 5.75
• 1Y Price Target: $7.50
• Price Target Upside: 9.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 74 Outperform
• Price Target: $7.50 ▲(9.97% Upside)

Viemed Healthcare's strong financial performance, strategic growth initiatives, and positive earnings call sentiment contribute significantly to its overall score. However, liquidity concerns due to negative free cash flow and mixed technical indicators slightly temper the outlook.

Viemed Healthcare Business Overview & Revenue Model

Company Description

Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company also leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), percussion vests, oxygen concentrator units, and other small respiratory equipment; and sells and rents DME and patient medical services. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management related solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

How the Company Makes Money

Viemed Healthcare generates revenue primarily through the leasing of medical equipment and the provision of respiratory therapy services. The company's key revenue streams include rental income from ventilators and oxygen devices, reimbursement from government and private insurance for therapy services, and sales of consumable supplies. Additionally, Viemed has established partnerships with healthcare providers and payers, which enhance its service offerings and facilitate access to a broader patient base, contributing significantly to its earnings.

Viemed Healthcare Financial Statement Overview

Summary

Viemed Healthcare demonstrates strong revenue growth and operational efficiency with healthy profit margins. The balance sheet is stable with low leverage and solid equity. Cash flow from operations is strong, though negative free cash flow signals caution in capital spending. Overall, the company is financially sound but could focus on improving net profitability and managing capital expenditures.

Income Statement

Viemed Healthcare has demonstrated solid revenue growth with a consistent upward trajectory from $117.06M in 2021 to $232.79M TTM. The gross profit margin is strong at 58.56% TTM, and the net profit margin has improved to 5.28% TTM. The EBIT and EBITDA margins are also healthy, indicating efficient operations. However, the net profit margin is relatively modest, suggesting room for profitability enhancement.

Balance Sheet

The company maintains a solid equity position with an equity ratio of 104.49% TTM, reflecting strong asset financing through equity. The debt-to-equity ratio is favorable at 0.05 TTM, indicating low leverage risk. Return on equity is moderate at 9.12% TTM. While the balance sheet shows stability, the moderate ROE suggests potential for better asset utilization to boost shareholder returns.

Cash Flow

Operating cash flow is robust at $40.77M TTM, but free cash flow has turned negative to -$6.48M TTM, largely due to increased capital expenditures. The operating cash flow to net income ratio is strong at 3.32 TTM, indicating effective cash conversion. The negative free cash flow suggests a need for careful capital management to ensure sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	240.88M	224.26M	183.01M	138.83M	117.06M	131.31M
Gross Profit	140.17M	133.20M	112.78M	84.68M	73.41M	80.11M
EBITDA	47.39M	42.31M	36.71M	24.03M	21.84M	30.54M
Net Income	13.98M	11.27M	10.24M	6.22M	9.13M	31.53M
Balance Sheet
Total Assets	184.60M	177.07M	154.90M	117.04M	117.96M	112.56M
Cash, Cash Equivalents and Short-Term Investments	20.02M	17.54M	12.84M	16.91M	28.41M	30.98M
Total Debt	6.89M	6.87M	10.32M	694.00K	6.52M	11.13M
Total Liabilities	42.98M	43.77M	41.00M	19.95M	23.14M	30.87M
Stockholders Equity	139.73M	131.39M	113.89M	97.09M	94.82M	81.69M
Cash Flow
Free Cash Flow	-3.60M	1.32M	19.12M	4.85M	2.75M	22.07M
Operating Cash Flow	42.84M	39.09M	45.21M	27.75M	22.49M	35.11M
Investing Cash Flow	-24.42M	-30.70M	-52.11M	-23.98M	-19.75M	-8.41M
Financing Cash Flow	-7.21M	-3.69M	2.83M	-15.27M	-5.32M	-9.07M

Viemed Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VMD, the sentiment is Negative. The current price of 6.82 is below the 20-day moving average (MA) of 7.05, above the 50-day MA of 6.79, and below the 200-day MA of 7.39, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 47.08 is Neutral, neither overbought nor oversold. The STOCH value of 29.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VMD.

Viemed Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TCMD	79 Outperform	$299.83M	21.27	7.64%	―	6.15%	-54.24%
VMD	74 Outperform	$264.13M	20.06	10.79%	―	17.11%	45.34%
ZIMV	67 Neutral	$534.13M	―	-4.76%	―	-19.52%	94.65%
SNWV	54 Neutral	$331.07M	―	0.65%	―	57.43%	-155.29%
Sector *	51 Neutral	$7.91B	-0.36	-41.70%	2.23%	23.45%	-1.86%
RCEL	42 Neutral	$114.20M	―	-935.73%	―	38.32%	-1.31%
NNOX	40 Underperform	$241.02M	―	-32.87%	―	17.36%	9.38%

Viemed Healthcare Corporate Events

Viemed Healthcare Completes Acquisition of Lehan’s Medical Equipment

On July 2, 2025, Viemed Healthcare announced the completion of its acquisition of Lehan’s Medical Equipment, a provider of home medical equipment based in Illinois, for a base purchase price of $26 million plus contingent payments. This acquisition is expected to enhance Viemed’s market presence by combining Lehan’s established brand and expertise with Viemed’s national scale and care delivery model. Viemed plans to update its full-year 2025 financial guidance to reflect the acquisition’s contribution when reporting earnings for the quarter ended June 30, 2025.

Viemed Healthcare Announces Share Repurchase Program

On June 6, 2025, Viemed Healthcare announced that its Board of Directors approved a share repurchase program, allowing the company to buy back up to 1,976,441 common shares, representing approximately 5% of the total issued and outstanding shares as of March 31, 2025. This move, effective through June 2026, is part of Viemed’s strategy to enhance shareholder value, supported by strong first-quarter results and ample liquidity, including a $55 million credit facility, while continuing to fund its growth initiatives.

Viemed Healthcare Shareholders Approve Key Decisions at Meeting

On June 5, 2025, Viemed Healthcare, Inc. held its Annual General and Special Meeting of Shareholders, where several key decisions were made. Shareholders approved an amendment to the 2024 Long Term Incentive Plan, which increases the number of shares available, clarifies vesting in the event of a change in control, and sets a minimum one-year vesting period. Additionally, all seven director nominees were elected, Ernst & Young LLP was appointed as the independent auditor, and the executive compensation package was approved. The frequency of future advisory votes on executive compensation was also set to occur annually.